Clinical Trial

With key investor conferences looming, Phathom Pharmaceuticals is set to showcase strong VOQUEZNA sales and a clear path to 2026 profitability.

New 12- and 24-month data for Benitec Biopharma's BB-301 gene therapy offers renewed hope for patients with a rare, debilitating muscular dystrophy.

C4 Therapeutics begins a crucial study for its oral protein degrader, cemsidomide, offering new hope for heavily treated multiple myeloma patients.

The biotech firm slashed a major acquisition hurdle in a deal with HealthCare Royalty, signaling strong confidence in its cancer drug ZYNLONTA's future.

The FDA is reviewing a new, more affordable alternative to the costly arthritis drug Orencia, potentially saving patients and the healthcare system billions.

New data reveals a targeted therapy can help patients with a rare, aggressive lung cancer even after their disease shows signs of worsening.

A new virotherapy platform delivers a one-two punch of a T-cell activator and a BiTE, aiming to overcome historical failures in solid tumor therapy.

ABLi Therapeutics reports its drug risvodetinib is the first to lower toxic alpha-synuclein levels in a Phase 2 trial, heralding a new era for patients.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

New real-world data on PEDMARK® suggests a breakthrough in preventing cisplatin-induced hearing loss for adults, a major step in cancer survivorship.

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

The biotech firm landed $1M at a premium, a sign of investor faith. But with past regulatory hurdles, can this cash pave a new path for its NurOwn® therapy?

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

A new study reveals a breakthrough hair loss system offers clinically meaningful regrowth for menopausal women in just four months, challenging existing treatments.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.

Serina Therapeutics enrolls the first patient in a trial for SER-252, a novel Parkinson's therapy designed to improve symptoms without current side effects.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

A groundbreaking, NIH-funded trial will use advanced PET imaging to test new Alzheimer's drugs, with XingImaging managing the critical visual data.

AVEO Oncology's ficlatuzumab advances in a pivotal Phase 3 trial, offering new hope for patients with a difficult-to-treat form of head and neck cancer.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.